Imidapril in heart failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 3, 2006, Pages 146-154

  Dolezul, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

ACE inhibitor; Acute myocardial infaction; Chronic heart failure; Hypertension; Imidapril; Left ventricular dysfunction

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANRENOATE POTASSIUM; CAPTOPRIL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAPRIL; IMIDAPRILAT; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; RAMIPRILAT; SPIRONOLACTONE; TRANDOLAPRIL; TRIAMTERENE;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BRADYCARDIA; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; LIVER DYSFUNCTION; NONHUMAN; PHYSICAL CAPACITY; PRIMARY PREVENTION; PROGNOSIS; PROTEINURIA; PRURITUS; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SYNCOPE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; DRUG RESISTANCE; DRUG TOXICITY; HUMANS; IMIDAZOLIDINES; POLYMORPHISM, GENETIC;

EID: 33750984774     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.024     Document Type: Review

References (39)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-18.
2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22(4 Suppl A):6A-13A.
3. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000;5:167-73.
4. Captopril Multicenter Study Group. A placebo-controlled trial of captopril in refractory congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
5. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
7. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
8. Massie BM. 15 years of heart-failure trials: what have we learned? Lancet 1998;352(Suppl 1):SI29-33.
9. Benzing T, Fleming I, Blaukat A, Muller-Esterl W, Busse R. Angiotensin-converting enzyme inhibitor ramiprilal interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999;99:2034-40.
10. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-6.
11. Shao Q, Ren B, Elimban V, Tappia PS, Takeda N, Dhalla NS. Modification of sarcolemmal Na+-K+-ATPase and Na+/Ca2+ exchanger expression in heart failure by blockade of renin-angiotensin system. Am J Physiol Heart Circ Physiol 2005;288:H2637-46.
12. Harder S, Thurmann PA, Ungethum W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol 1998;45:377-80.
13. Vandenburg MJ, Mackay EM, Dews I, Pullan T, Brugier S. Dose finding studies with imidapril - a new ACE inhibitor. Br J Clin Pharmacol 1994;37:265-72.
14. Hoogkamer JF, Kleinbloesem CH, Nokhodian A et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure. Eur J Clin Pharmacol 1998; 54:59-61.
15. Harder S, Thurmann PA. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Br J Clin Pharmacol 1997;43:475-80.
16. Hoogkamer JF, Kleinbloesem CH, Nokhodian A et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Eur J Clin Pharmacol 1997;51:489-91.
17. Song KH, Fedyk R, Hoover R. Interaction of ACE inhibitors and aspirin in patients with congestive heart failure. Ann Pharmacother 1999;33:375-7.
18. Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993;25:20-58.
19. Mignat C, Unger T. ACE inhibitors. Drug interactions of clinical significance. Drug Saf 1995;12:334-47.
20. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41.
21. Lonn E, McKelvie R. Drug treatment in heart failure. BMJ 2000;320:1188-92.
22. Davies MK, Gibbs CR, Lip GY. ABC of heart failure. Management: diuretics, ACE inhibitors, and nitrates. BMJ 2000;320:428-31.
23. Sanharwal NK, Swinburn J, Lahari A, Senior R. Effect of imidapril and nifedipine on left-ventricular hypertrophy in untreated hypertension. Clin Drug Invest 2005;25:367-75.
24. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J 1992;67:289-96.
25. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
26. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
27. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
28. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
29. Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, Rooks G, Netzer T, Lie KI. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996;50:265-8.
30. van Veldhuisen DJ, Genth-Zotz S, Brouwer J et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998;32:1811-18.
31. Kitaoka H, Takata J, Hitomi N et al. Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2000;85:658-60,A10.
32. Yoshitomi Y, Kojima S, Yano M, Sugi T, Matsumoto Y, Kuramochi M. Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: An angiographic study in patients with maintained vessel patency. Am Heart J 2000;140:E27.
33. Katayama S, Kikkawa R, Isogai S et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 2002; 55:113-21.
34. Geshi E, Kimura T, Yoshimura M et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res 2005;28:719-25.
35. Yu HM, Lin SG, Liu GZ, Zhang YQ, Ma WJ, Deng CY. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin Pharmacol Ther 2006;79:581-9.
36. Huang PJ, Chien KL, Chen MF, Lai LP, Chiang FT. Efficacy and safety of imidapril in patients with essential hypertension: a double-blind comparison with captopril. Cardiology 2001; 95:146-50.
37. Saruta T, Arakawa K, Iimura O et al. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999; 22:197-202.
38. Sugaya T, Minobe S, Taniguchi T, Hashimoto Y, Kubo M, Watanabe T. Studies on angiotensin I converting enzyme (ACE) inhibitory effect of imidapril. (I). Inhibition of various tissue ACEs in vitro. Nippon Yakurigaku Zasshi 1992;100:39-45.
39. Saruta T, Arakawa K, Imura O et al. A multicenter comparative study of imidapril and enalapril on usefulness, and incidence of cough. J New Remedies and Clinics 1998; 47:249-82.